Donated plasma is used to create life-saving treatments for people with rare diseases, bleeding disorders, immune deficiencies, and severe burns or trauma. It’s also used directly in emergency rooms to replace lost blood volume. Plasma is the liquid portion of blood, and it contains proteins that can’t be manufactured synthetically in most cases, which is why donated plasma remains essential. Treating just one patient with a primary immune deficiency requires more than 130 individual plasma donations per year.
How Donated Plasma Becomes Medicine
After collection, plasma goes through a process called fractionation, where it’s separated into its individual protein components. These proteins are then purified, tested for viruses, and turned into specific medical products. The major categories include albumin (a protein that helps maintain blood pressure and fluid balance), immunoglobulins (concentrated antibodies that bolster the immune system), clotting factors (proteins that help blood form clots), and several more specialized therapies.
The U.S. FDA regulates dozens of fractionated plasma products. Some of the most commonly used include immune globulins, clotting factor concentrates for hemophilia, albumin for burn and trauma patients, and C1 esterase inhibitor therapies for hereditary angioedema. Because plasma contains so many different functional proteins, a single donation can contribute to multiple finished products.
Treating Immune Deficiencies
One of the largest uses of donated plasma is producing immunoglobulin therapy for people with primary immunodeficiency diseases. These are genetic conditions where a person’s immune system can’t fight infections effectively. The World Health Organization estimates there may be as many as 150 different primary immunodeficiencies. People with these conditions can’t rely on standard antibiotics alone, so they receive concentrated antibodies extracted from pooled plasma donations, typically through regular infusions that continue for life.
The sheer volume of plasma needed is striking. Because immunoglobulin products are made from pooled donations from many donors, and each patient needs ongoing treatment, the 130-plus donations per patient per year figure helps explain why plasma collection centers operate at high volume. If you’ve ever wondered why plasma donation centers seem to be everywhere, this is a big part of the reason.
Bleeding Disorders and Clotting Factors
Plasma-derived clotting factor concentrates are critical for people with hemophilia. Hemophilia A, the most common form, results from a lack of clotting factor VIII. Without treatment, even minor injuries can cause prolonged bleeding, and spontaneous bleeding into joints causes lasting damage over time. Plasma donations provide the raw material for freeze-dried clotting factor products that patients can infuse at home to prevent or stop bleeding episodes.
Other clotting-related conditions treated with plasma-derived products include von Willebrand disease, antithrombin III deficiency (where the blood clots too easily rather than too little), and various rare factor deficiencies. The CDC notes that all plasma used for these products goes through multiple rounds of viral testing and inactivation before reaching patients.
Emergency and Trauma Care
In hospitals, plasma is transfused directly to patients experiencing massive blood loss from trauma, surgery, or severe burns. Burn patients lose enormous amounts of plasma through damaged capillaries, both during the initial shock phase and during wound care and surgery. Without plasma transfusions to restore circulating blood volume, the body can’t maintain normal blood pressure or deliver oxygen to organs.
Trauma centers also use plasma alongside red blood cells and platelets during what’s called massive transfusion protocols. Albumin, one of the key proteins extracted from plasma, plays a separate role in burn care by helping pull fluid back into blood vessels and reducing dangerous swelling.
Autoimmune and Neurological Conditions
Plasma plays a role in treating several autoimmune conditions through two different approaches. The first is immunoglobulin therapy, where concentrated antibodies from donated plasma help regulate an overactive immune system. This is a standard treatment for conditions like chronic inflammatory demyelinating polyneuropathy (CIDP), a rare disorder that damages the protective coating around nerves, and Kawasaki disease, the leading cause of acquired heart disease in children under five.
The second approach is therapeutic plasma exchange, where a patient’s own plasma is removed and replaced with donor plasma or a substitute fluid. This physically strips out the harmful antibodies, immune complexes, and inflammatory molecules driving the disease. Each exchange removes roughly 60% to 70% of the targeted substances from the bloodstream. Conditions treated this way include Guillain-Barré syndrome, myasthenia gravis, and certain kidney diseases. The effects often last longer than the simple removal of antibodies would predict, suggesting the procedure also resets parts of the immune system in ways researchers are still working to fully understand.
Other Rare Disease Treatments
Several other rare conditions depend on plasma-derived therapies. Alpha-1 antitrypsin deficiency, sometimes called genetic emphysema, is one of the most common serious hereditary disorders worldwide. It can cause life-threatening lung disease in adults and liver disease in both children and adults. Patients receive a protective protein extracted from donated plasma to slow lung damage.
Hereditary angioedema is caused by a missing protein that helps regulate inflammation. Without treatment, patients experience severe, unpredictable swelling that can become fatal if it affects the airway. The replacement protein, C1 esterase inhibitor, comes from fractionated plasma. Idiopathic thrombocytopenic purpura, an autoimmune condition that destroys blood platelets needed for clotting, is also treated with plasma-derived immunoglobulins.
Why Demand Keeps Growing
The global plasma therapy market was valued at $620 million in 2025 and is projected to nearly double by 2034. Several factors are driving this growth: better diagnosis of rare diseases means more patients identified and treated, aging populations need more clotting and immune therapies, and plasma-based treatments are expanding into areas like wound healing and orthopedic care.
At the same time, plasma collection faces real constraints. The infrastructure for collecting, processing, and storing plasma is expensive and specialized, which limits how quickly supply can scale. Newer alternatives like monoclonal antibodies and other biologic drugs are beginning to replace plasma-derived products for some conditions, but for many patients, particularly those with primary immunodeficiencies and rare clotting disorders, there is no synthetic substitute. Their treatment depends entirely on people walking into donation centers.
Who Can Donate Plasma
Plasma donation eligibility in the United States requires you to be at least 18 years old and weigh at least 110 pounds. You can donate plasma as often as every two days, with a maximum of twice within any seven-day period. The process takes longer than a standard blood donation, typically 60 to 90 minutes, because your blood is drawn, the plasma is separated out, and the remaining blood components are returned to your body.
Most paid plasma donation in the U.S. goes to fractionation for medical products, while plasma collected at volunteer blood drives is more often used for direct hospital transfusions. Both supply chains are essential, and both face chronic shortages relative to the number of patients who depend on them.